Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma

Jin, Jingxia; Zheng, Cuiping; Wu, Shenghao

doi:10.1097/md.0000000000009611

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This large study demonstrates that chidamide has acceptable efficacy and safety profiles for relapsed and refractory PTCL patients [ 9 ]. In addition, Jin et al described a refractory AITL case who received chidamide with chemotherapy and achieved complete remission [ 10 ]. Chidamide combined with chemotherapy may be a new treatment for refractory and relapsed PTCL and ALTL patients.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Gui

Wang

et al. 2020

Open Medicine

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to evaluate the clinicopathological features and treatment of composite lymphoma (CL) with cervical lymph node enlargement.MethodsIn this study, two cases of CL are presented. Biopsies of enlarged cervical lymph nodes by excision revealed two distinct types of lymphomas. The diagnoses were confirmed by routine histopathology, immunohistochemistry, in situ hybridization, polymerase chain reactions and flow cytometry. Case 1 was diagnosed with Hodgkin’s lymphoma and cytotoxic T-cell lymphoma complicated by Epstein–Barr virus infection. Case 2 was diagnosed with diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma.ResultsCase 1 received one cycle of adriamycin, bleomycin, vincristine and dacarbazine (ABVD regimen) combined with chidamide, followed by one cycle of gemcitabine and dexamethasone (GDP regimen) combined with chidamide, and then oral acyclovir. The patient achieved stable disease, but was lost to follow-up. Case 2 received eight cycles of cyclophosphamide, pirarubicin, vincristine and dexamethasone (CTOP regimen) combined with chidamide, and the patient achieved complete remission. Nine months later, relapse was confirmed. She received chidamide monotherapy for 3 months, which was then terminated. One year later, the patient underwent progressive disease and died.ConclusionsCL is a kind of rare disease. Due to the complexity of CL, clinicians should consider both disease components in order to increase the likelihood of effective treatment. This is important.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Gui

Wang

et al. 2020

Open Medicine

View full text Add to dashboard Cite

show abstract

“…Chidamide is a novel orally histone deacetylase inhibitor (HDACi), which has inhibitory activity against HDAC1, 2, 3, 10 ( 26 ). It has shown activity against several types of tumors in vitro and in vivo ( 26 – 30 ). Chidamide might suppress T lymphoma cell growth and promote the apoptosis of T lymphoma cells though interfering with the binding between histone and DNA ( 31 ).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up

Zhu

Xiao

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Refractory/relapsed angioimmunoblastic T cell lymphoma (AITL) with Evans syndrome is a very rare condition with a poor prognosis. There is no evidencebased treatment strategy for refractory/relapsed AITL with Evans syndrome. Case Presentation: A 51-year-old female was admitted to our hospital with multiple enlarged bilateral cervical lymph nodes, more than 1 week-long chest distress, and night sweats in July 2014. An excision biopsy of the left cervical enlarged lymph node revealed AITL. However, the patient showed resistance to the first-line chemotherapy for AITL and was diagnosed with refractory AITL. Complete remission was achieved after the salvage treatment with the combination of chemotherapy, radiotherapy, and immunomodulatory agent lenalidomide. Unfortunately, 12 months later, the patient suffered from disease progression and was diagnosed as refractory/relapsed AITL with Evans syndrome according to the laboratory findings and imaging. With the diagnosis of refractory/relapsed AITL with Evans syndrome, the patient received the first-line treatment for Evans syndrome including prednisone and intravenous immunoglobulin. The response to the first-line treatment for Evans syndrome was poor. The combination regimen of chidamide (30 mg, po, biw) and cyclosporine were administrated considering the treatment targeting simultaneously both refractory/relapsed AITL and Evans syndrome. The efficacy evaluation was complete remission. The last follow-up of the patient was April 30th, 2020, and no evidence of disease progression was observed. The overall survival of the patient was more than 70 months. Conclusion: The treatment for refractory/relapsed AITL combined with Evans syndrome remains challenging to patients and physicians. The combination of chidamide and cyclosporine may be an effective and tolerable regimen for the intractable AITL with Evans syndrome case and more observations are necessary to identify the efficacy and safety in the future.

show abstract

“…The combination of chidamide and decitabine, a hypomethylating agent inhibited the growth of p300- or KMT2D-mutated T-lymphoma cells [ 16 ]. Moreover, clinical studies showed that chidamide had a favorable efficacy for angioimmunoblastic T-cell lymphoma [ 17 ] and relapsed/refractory peripheral T-cell lymphoma patients [ 18 , 19 ]. However, it has not been determined whether chidamide, either as a single agent or as a component of combined therapy, could induce autophagy in the rituximab/chemotherapy relapsed and refractory B-cell lymphoma cells.…”

Section: Introductionmentioning

confidence: 99%

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

Xue

et al. 2021

Cell Death Dis

View full text Add to dashboard Cite

Rituximab/chemotherapy relapsed and refractory B cell lymphoma patients have a poor overall prognosis, and it is urgent to develop novel drugs for improving the therapy outcomes. Here, we examined the therapeutic effects of chidamide, a new histone deacetylase (HDAC) inhibitor, on the cell and mouse models of rituximab/chemotherapy resistant B-cell lymphoma. In Raji-4RH/RL-4RH cells, the rituximab/chemotherapy resistant B-cell lymphoma cell lines (RRCL), chidamide treatment induced growth inhibition and G0/G1 cell cycle arrest. The primary B-cell lymphoma cells from Rituximab/chemotherapy relapsed patients were sensitive to chidamide. Interestingly, chidamide triggered the cell death with the activation of autophagy in RRCLs, likely due to the lack of the pro-apoptotic proteins. Based on the RNA-seq and chromatin immunoprecipitation (ChIP) analysis, we identified BTG1 and FOXO1 as chidamide target genes, which control the autophagy and the cell cycle, respectively. Moreover, the combination of chidamide with the chemotherapy drug cisplatin increased growth inhibition on the RRCL in a synergistic manner, and significantly reduced the tumor burden of a mouse lymphoma model established with engraftment of RRCL. Taken together, these results provide a theoretic and mechanistic basis for further evaluation of the chidamide-based treatment in rituximab/chemotherapy relapsed and refractory B-cell lymphoma patients.

show abstract

Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma

Cited by 5 publications

References 22 publications

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Clinicopathological analysis of composite lymphoma: A two-case report and literature review

Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

Contact Info

Product

Resources

About